Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 3, 2013, Pages 146-155

  Pal, Sumanta Kumar ^a   Vogelzang, Nicholas J ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; mTOR; Renal cell carcinoma; Sequential monotherapy; Targeted therapy; VEGF

Indexed keywords

ALPHA2 INTERFERON; AXITINIB; BEVACIZUMAB; CABOZANTINIB; DOVITINIB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NIVOLUMAB; PAZOPANIB; PERIFOSINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ALOPECIA; ANEMIA; ARTICLE; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; GENE EXPRESSION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY METASTASIS; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; SURVIVAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 84877939992     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/. Accessed July 23, 2012.
3. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.
4. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163-1167.
5. Sorbellini M, KattanMW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol. 2005;173:48-51.
6. Inlyta (axitinib) tablets for oral administration [prescribing information]. New York, NY: Pfizer, Inc; 2012.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312-3318.
9. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
10. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144-2150.
11. Rini BI, Halabi S, Rosenberg JE. CALGB 90206: bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27: Abstract LBA5019.
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
13. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
14. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
16. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med. 2007;356:125-134.
17. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
18. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
19. National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer, V.2.2012. http://www.nccn.org. Accessed March 5, 2012.
20. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v137-v139.
21. de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45:765-773.
22. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398-406.
23. Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol. 2007;17:331-336.
24. Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 2009;115:2306-2312.
25. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-591.
26. Oudard S, Ravaud A, Escudier B. Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: focus on mechanism of action. Ann Urol. 2010;1:19-27.
27. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-484.
28. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009;145:569-580.
29. Afinitor (everolimus) tablets for oral administration prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2012.
30. Lebwohl D, Thomas G, Lane HA, et al. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov. 2011;6:323-338.
31. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278-2287.
32. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010;16:3628-3638.
33. Torisel (temsirolimus) injection prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals Inc; September 2010.
34. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
35. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063-1071.
36. Liu Y, Tran HT, Lin Y, et al. Plasma cytokine and angiogenic factors predictive of clinical benefit and prognosis in patients with advanced or metastatic renal cell cancer treated in phase III trials of pazopanib. J Clin Oncol (ASCO Annual Meeting Abstracts). 2011;29: Abstract 334.
37. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 2011;11:856-861.
38. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9:639-651.
39. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992-1000.
40. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299-309.
41. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46:1323-1332.
42. www.ClinicalTrials.gov. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ). http://clinicaltrials.gov/ct2/show/NCT00720941. Identifier: NCT00720941.
43. www.ClinicalTrials.gov. A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1). http://clinicaltrials.gov/ ct2/show/ NCT01030783. Identifier: NCT01030783.
44. Escudier B., Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, crossover study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310 (abstract). J Clin Oncol. 2012;30. Abstract CRA4502.
45. AVEO and Astellas announce tivozanib successfully demonstrated progression-free survival superiority over sorafenib in patients with advanced renal cell cancer in phase 3 TIVO-1 trial press release. Cambridge, MA. and Tokyo, Japan: Business Wire; Aveo Pharmaceuticals, Inc. Astellas Pharma Inc., January 3, 2012.
46. Knox JJ, Kay AC, Schiff E, et al. First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC) (abstract). J Clin Oncol. 2010(29):15s. Abstract TPS232.
47. www.ClinicalTrials.gov. A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced/metastatic renal cell carcinoma. http://clinicaltrials.gov/ct2/show/NCT00732914. Identifier: NCT00732914.
48. Michel MS, Vervenne W, Goebell PJ, et al. Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/ metastatic renal cell carcinoma without prior systemic therapy (SWITCH study): safety interim analysis results (abstract). J Clin Oncol. 2012;30. Abstract 4539.
49. www.ClinicalTrials.gov. A phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by sunitinib versus sunitinib followed by sorafenib in the treatment of first-line advanced/metastatic renal cell carcinoma. http://clinicaltrials.gov/ct2/show/NCT00732914. Identifier: NCT00732914.
50. www.ClinicalTrials.gov. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib (INTORSECT). http://clinicaltrials.gov/ct2/show/NCT00474786. Identifier: NCT00474786.
51. Pfizer provides topline results from phase three study of Torisel as a secondline treatment in advanced renal cell carcinoma (RCC) press release. New York, NY: Business Wire; Pfizer Inc., May 15, 2012.
52. www.ClinicalTrials.gov. An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma - RECORD-4. http://clinicaltrials.gov/ct2/show/NCT01491672. Identifier: NCT01491672.
53. Australian New Zealand Clinical Trials Registry. A phase 2 trial evaluating the effect of everolimus alternating with sunitinib on progression-free survival in patients with advanced renal cell carcinoma. Australian New Zealand Clinical Trials Registry. http://www.anzctr.org.au/trial_view.aspx?ID=308211. Accessed July 23, 2012.
54. Angevin E, Grunwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC) (abstract). J Clin Oncol. 2011(29). Abstract 3057.
55. www.ClinicalTrials.gov. An open-label, randomized, multi-center, phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGFtargeted and mTOR inhibitor) therapies. http://clinicaltrials.gov/ct2/show/ NCT01223027. Identifier: NCT01223027.
56. www.ClinicalTrials.gov. A randomized, open-label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney. http://clinicaltrials.gov/ct2/show/NCT00719264. Identifier: NCT00719264.
57. www.ClinicalTrials.gov. Study comparing bevacizumab + temsirolimus vs. bevacizumab + interferon-alfa in advanced renal cell carcinoma subjects (INTORACT). http://clinicaltrials.gov/ct2/show/NCT00631371. Identifier: NCT00631371.
58. www.ClinicalTrials.gov. Everolimus with or without bevacizumab in treating patients with advanced kidney cancer that progressed after first-line therapy. http://clinicaltrials.gov/ct2/show/NCT01198158. Identifier: NCT01198158.
59. Hainsworth JD, Spigel DR, Burris HA, III, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131-2136.
60. Kabbinavar FF, Srinivas S, Hauke RJ, et al. Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC) (abstract). J Clin Oncol. 2011;29(suppl 15). Abstract 4549.
61. Negrier S, Gravis G, Perol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol. 2011;12:673-680.
62. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432-1439.
63. Michaelson MD. Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street? Cancer. 2012;118:1744-1746.
64. Molina AM, Feldman DR, Voss MH, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118:1868-1876.
65. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitour Cancer. 2009;7:24-27.
66. Porta C, Figlin RA. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol. 2009;182:2569-2577.
67. Peyton JD, Ahnert JR, Burris H, et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patient with advanced solid tumors (abstract). J Clin Oncol. 2011;29(suppl 15). Abstract 3066.
68. www.ClinicalTrials.gov. A phase I/II study of BEZ235 in patients with advanced solid malignancies enriched by patients with advanced breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00620594. Identifier: NCT00620594.
69. Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castrationresistant prostate cancer. Clin Transl Oncol. 2011;13:703-709.
70. Choueiri TK, Pal SK, McDermott DF, et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC) (abstract). J Clin Oncol. 2012;30. Abstract 4504.
71. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumorinfiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757-1761.
72. McDermott DF, Drake CG, Sznol M, et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC) (abstract). J Clin Oncol. 2012;30. Abstract 4505.
73. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.
74. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer. 2010;1:152-163.
75. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14:435-446.
76. Saez MI, Trigo Perez JM, Perez-Rivas LG, et al. Hypoxia-inducible factor (HIF) 1a and 2a as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC) (abstract). J Clin Oncol. 2012;30. Abstract 4630.
77. Hudes GR, Pei J, Liu Y, et al. Correlation of chromosome (Chr) 14 loss and 5q gain with outcomes of pazopanib treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) (abstract). J Clin Oncol. 2012;30. Abstract 4605.
78. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98:756-762.
79. Pomerantz MM, Gray KP, Barros FAS, et al. Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition (abstract). J Clin Oncol. 2012;30. Abstract 4543.